Findings for pregnant patients with type 1 diabetes
FRIDAY, Aug. 19, 2016 (HealthDay News) — For pregnant women with type 1 diabetes, closed-loop therapy is associated with a greater percentage of time that overnight glucose levels are in the target range, compared with sensor-augmented pump therapy, according to a study published in the Aug. 18 issue of the New England Journal of Medicine.
Zoe A. Stewart, M.D., from the University of Cambridge in the United Kingdom, and colleagues performed a randomized, crossover trial in 16 pregnant women with type 1 diabetes. Participants completed four weeks of closed-loop pump therapy and sensor-augmented pump therapy in random order. Fourteen participants used the closed-loop system until delivery during the continuation phase.
The researchers found that, compared with during control therapy, during closed-loop therapy the overnight glucose levels were in the target range for a higher percentage of time (74.7 versus 59.5 percent; P = 0.002). During closed-loop therapy the overnight mean glucose level was lower than during control therapy (119 versus 133 mg/dL; P = 0.009). No significant between-group differences were seen in the percentage of time in which glucose levels were below the target range, in insulin doses, or in adverse event rates. Glucose levels were in the target range 68.7 percent of the time during the continuation phase (up to 14.6 additional weeks).
“Overnight closed-loop therapy resulted in better glucose control than sensor-augmented pump therapy in pregnant women with type 1 diabetes,” the authors write.
Copyright © 2016 HealthDay. All rights reserved.
